PCN89 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN BELGIUM.

Authors :: Van Campenhout, H.
Teitsson, S.
Orsini, I.
Augusto, M.
Amadi, A.
Source :: Value in Health. 2019 Supplement 3, Vol. 22, pS453-S453. 1p.
Publication Year :: 2019
Abstract: The aim of this study was to assess the cost-effectiveness of nivolumab versus "watch and wait" as an adjuvant treatment for melanoma in adults with involvement of lymph nodes or metastatic disease, after having undergone complete resection in Belgium. The efficacy of nivolumab and observation on recurrence free survival (RFS) was informed by an indirect treatment comparison based on patient-level data from CheckMate 238 (24-month cut-off data) and CA184-029 trials, as both include ipilimumab as comparator. [Extracted from the article]

Subjects :: *IPILIMUMAB
*LYMPH nodes
*COST effectiveness
*MELANOMA
*ADULTS
*DISCOUNT prices

Full Text Access

Tools